Observational Prospective Study of Immune Checkpoint Inhibitors for Solid Neoplasms
Recruiting
Observational Study
Cancer
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 6,000 (estimated)
- Sponsor
- Fudan University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This prospective, multicenter observational study included all patients with solid neoplasms who received treatment with immune checkpoint inhibitors (ICIs) in clinical practice, regardless of tumor type, tumor stage, type of immunotherapy, or treatment lines. This study aimed to assess the use, effectiveness, and safety of ICIs for solid neoplasms in real-world populations, which can provide insi…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age at least 18 years.
* Pathologically confirmed diagnosis of a solid tumor cancer.
* Patients receiving treatment with immune checkpoint inhibitors.
* Ability to understand and willingness to provide the informed consent.
Exclusion Criteria:
* Age \< 18 years.
* Patients w…
Contacts